Kohei Tsuji
Overview
Explore the profile of Kohei Tsuji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kobayakawa T, Arioka M, Yamamoto K, Tsuji K, Tamamura H
Org Biomol Chem
. 2025 Feb;
PMID: 39945507
An efficient method for diastereo-controlled synthesis of ()-fluoroalkene dipeptide isosteres (FADIs) was developed. Two chiral centers were constructed by applying our synthetic methodology for chloroalkene dipeptide isosteres (CADIs) using Ellman's...
2.
Higashi-Kuwata N, Bulut H, Hayashi H, Tsuji K, Ogata-Aoki H, Kiso M, et al.
PNAS Nexus
. 2025 Jan;
4(1):pgae578.
PMID: 39831159
We identified a 5-fluoro-benzothiazole-containing small molecule, TKB272, through fluorine-scanning of the benzothiazole moiety, which more potently inhibits the enzymatic activity of SARS-CoV-2's main protease (M) and more effectively blocks the...
3.
Tsuji K, Tamamura H, Burke T
Bioorg Med Chem
. 2025 Jan;
119:118055.
PMID: 39764864
Polo-like kinase 1 (Plk1) is an important cell cycle regulator that is a recognized target for development of anti-cancer therapeutics. Plk1 is composed of a catalytic kinase domain (KD), a...
4.
Shinohara K, Kobayakawa T, Tsuji K, Takamatsu Y, Mitsuya H, Tamamura H
Eur J Med Chem
. 2024 Oct;
280:116963.
PMID: 39442336
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has not yet been eradicated. SARS-CoV-2 has two types of proteases, a main protease (M) and a...
5.
Tsuji K, Tamamura H, Burke Jr T
RSC Chem Biol
. 2024 Aug;
5(8):721-728.
PMID: 39092437
The polo-like kinase 1 (Plk1) is an important cell cycle regulator that is recognized as a target molecule for development of anti-cancer agents. Plk1 consists of a catalytic kinase domain...
6.
Tsuji K, Tamamura H, Burke Jr T
Biol Pharm Bull
. 2024 Jul;
47(7):1282-1287.
PMID: 38987177
Assay systems for evaluating compound protein-binding affinities are essential for developing agonists and/or antagonists. Targeting individual members of a protein family can be extremely important and for this reason it...
7.
Kobayakawa T, Tsuji K, Tamamura H
Bioorg Med Chem
. 2024 Jul;
110:117811.
PMID: 38959684
Ample biologically active peptides have been found, identified and modified for use in drug discovery to date. However, several factors, such as low metabolic stability due to proteolysis and non-specific...
8.
Ishii T, Kobayakawa T, Matsuda K, Nigorikawa K, Bolah P, Noborio A, et al.
ACS Infect Dis
. 2024 May;
10(6):2250-2261.
PMID: 38771724
Toward human immunodeficiency virus type-1 (HIV-1) cure, cells latently infected with HIV-1 must be eliminated from people living with HIV-1. We previously developed a protein kinase C (PKC) activator, diacylglycerol...
9.
Kobayakawa T, Takano H, Ishii T, Bolah P, Tsuji K, Ohashi N, et al.
Chem Pharm Bull (Tokyo)
. 2024 Mar;
72(3):311-312.
PMID: 38494724
An improvement of the two-photon excitation was achieved using 8-azacoumarin-type caged compounds, which showed large values of the two-photon uncaging action cross-section (δ >0.1 Goeppert-Mayer (GM)). In particular, the 7-hydroxy-6-iodo-8-azacoumarin...
10.
Kitagawa K, Tsuji K, Sagehashi K, Niiyama T, Sunada S
Opt Express
. 2024 Feb;
32(3):3209-3220.
PMID: 38297547
Hyperdimensional computing (HDC) is an emerging computing paradigm that exploits the distributed representation of input data in a hyperdimensional space, the dimensions of which are typically between 1,000-10,000. The hyperdimensional...